Dublin-based Jazz Pharmaceuticals announced in April it would be acquiring specialty pharmaceutical company EUSA Pharma, of Langhorne, Pennsylvania, and Oxford, for $650 million in cash. EUSA's only marketed product is Erwinaze (asparaginase Erwinia chrysanthemi), approved in November 2011 by the US Food and Drug Administration for treating acute lymphoblastic leukemia in combination with other anti-neoplastic agents. Because it is produced in Erwinia chrysanthemi, this drug does not induce the immune reaction observed among 15–20% patients taking the L-asparaginase grown in Escherichia coli. Although Erwinaze is an attractive asset, Jazz appeared to be paying a high price for what seems to be a one-approved-product company. But EUSA has two other key drug candidates in its pipeline: a pegylated recombinant version of Erwinaze (Asparec) in phase 1 studies in Europe and an anti-CD25 monoclonal antibody (inolimomab; Leukotac) in a phase 3 pivotal study in Europe to treat steroid-refractory cases of acute graft-versus-host disease.